Facebook-f Twitter Tiktok Instagram Youtube
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

ENTA – Enanta Pharmaceuticals Inc

Float Short %

9.07

Margin Of Safety %

Put/Call OI Ratio

0.37

EPS Next Q Diff

0.33

EPS Last/This Y

1.54

EPS This/Next Y

-0.2

Price

14.75

Target Price

19.12

Analyst Recom

1.38

Performance Q

97.45

Relative Volume

0.34

Beta

0.97

Ticker: ENTA



20 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-11-13ENTA11.710.860.002675
2025-11-14ENTA12.050.890.062624
2025-11-17ENTA12.820.890.002631
2025-11-18ENTA12.360.520.033695
2025-11-19ENTA12.150.5211.773716
2025-11-20ENTA12.110.581.013882
2025-11-21ENTA12.710.611.564024
2025-11-24ENTA13.660.190.962442
2025-11-25ENTA13.640.180.032459
2025-11-26ENTA13.910.250.932686
2025-12-01ENTA14.140.262.002713
2025-12-02ENTA13.950.2643.002726
2025-12-03ENTA14.250.370.002963
2025-12-04ENTA14.110.370.002963
2025-12-05ENTA14.580.370.562981
2025-12-08ENTA14.180.370.002996
2025-12-09ENTA14.650.370.752997
2025-12-10ENTA14.390.371.502999
2025-12-11ENTA14.160.370.173000
2025-12-12ENTA14.750.372.003004
DateSymbolLatestP/C OIP/C VolTotal OI
20 items Current Page1 of 1



20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-11-13ENTA11.6925.4- -3.72
2025-11-14ENTA12.0325.4- -3.72
2025-11-17ENTA12.8425.4- -3.72
2025-11-18ENTA12.3725.4- -3.72
2025-11-19ENTA12.1325.4- -3.72
2025-11-20ENTA12.1225.4- -3.15
2025-11-21ENTA12.7249.5- -2.98
2025-11-24ENTA13.7149.5- -2.98
2025-11-25ENTA13.6649.5- -2.30
2025-11-26ENTA13.9449.5- -2.30
2025-12-01ENTA14.1549.1- -2.30
2025-12-02ENTA13.9649.1- -2.30
2025-12-03ENTA14.2449.1- -2.30
2025-12-04ENTA14.0849.1- -2.30
2025-12-05ENTA14.6049.1- -2.30
2025-12-08ENTA14.1849.1- -2.30
2025-12-09ENTA14.6449.1- -2.30
2025-12-10ENTA14.6449.1- -2.30
2025-12-11ENTA14.1449.1- -2.30
2025-12-12ENTA14.7549.1- -2.30
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1



20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-11-13ENTA0.00-1.4910.14
2025-11-14ENTA0.00-1.499.98
2025-11-17ENTA0.0027.119.98
2025-11-18ENTA0.0027.119.98
2025-11-19ENTA0.0027.119.98
2025-11-20ENTA0.0027.119.98
2025-11-21ENTA0.0027.119.98
2025-11-24ENTA0.0015.659.98
2025-11-25ENTA0.0015.659.98
2025-11-26ENTA0.0015.6510.23
2025-12-01ENTA0.0015.6210.23
2025-12-02ENTA0.0015.6210.23
2025-12-03ENTA0.0015.6210.23
2025-12-04ENTA-0.0415.6210.23
2025-12-05ENTA-0.0415.6210.23
2025-12-08ENTA-0.8715.4910.25
2025-12-09ENTA-0.8515.4910.25
2025-12-10ENTA-0.8515.499.07
2025-12-11ENTA-0.8515.499.07
2025-12-12ENTA-0.8515.499.07
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

[stock_market_widget type="chart" template="candlestick" assets="ENTA" range="1y" interval="1d" price_field="close" heading="{symbol}" candle_border_width="1" candle_bullish_background_color="#21BA45" candle_bearish_background_color="#DB2828" candle_bullish_border_color="#21BA45" candle_bearish_border_color="#DB2828" axes_color="#000000" tooltip_text_color="#262626" tooltip_background_color="#ffffff" range_selector="true" volume_enabled="true" axes_enabled="true" tooltip_enabled="false" zoom_enabled="true" save_image_enabled="true" volume_bar_fill_color="#5679FF" api="yahoo-finance"]

Last Quarter Act. EPS​

-0.87

Avg. EPS Est. Current Quarter

-0.54

Avg. EPS Est. Next Quarter

-0.54

Insider Transactions

-0.85

Institutional Transactions

15.49

Beta

0.97

Average Sales Estimate Current Quarter

16

Average Sales Estimate Next Quarter

15

Fair Value

Quality Score

19

Growth Score

24

Sentiment Score

35

Actual DrawDown %

85.5

Max Drawdown 5-Year %

-95.6

Target Price

19.12

P/E

Forward P/E

PEG

P/S

6.51

P/B

4.87

P/Free Cash Flow

EPS

-3.84

Average EPS Est. Cur. Y​

-2.3

EPS Next Y. (Est.)

-2.5

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-125.36

Relative Volume

0.34

Return on Equity vs Sector %

-153.4

Return on Equity vs Industry %

-138.4

EPS 1 7Days Diff

1

EPS 1 30Days Diff

0.97

EBIT Estimation

[stock_market_widget type=”table-options” template=”gradient” color=”#5679FF” assets=”ENTA” fields=”contract_symbol,type,strike,price,change_pct,implied_volatility,change_abs,open_interest,volume,in_the_money,bid,ask” pagination=”true” rows_per_page=”21″ sort_direction=”asc” alignment=”left” search=”true” sort_field=”strike” api=”yahoo-finance”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”ENTA” options_type=”calls” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”ENTA” options_type=”puts” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”ENTA” options_type=”calls” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”ENTA” options_type=”puts” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”ENTA” options_type=”calls” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”ENTA” options_type=”puts” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
Enanta Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 120
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
stock quote shares ENTA – Enanta Pharmaceuticals Inc Stock Price stock today
news today ENTA – Enanta Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch ENTA – Enanta Pharmaceuticals Inc yahoo finance google finance
stock history ENTA – Enanta Pharmaceuticals Inc invest stock market
stock prices ENTA premarket after hours
ticker ENTA fair value insiders trading